http://venturebeat.com/2007/11/14/enteromedics-and-its-risky-obesity-device-the-latest-victims-of-the-ipo-haircut/ News About Tech, Money and Innovation Wed, 25 Nov 2009 08:52:15 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://venturebeat.com/2007/11/14/enteromedics-and-its-risky-obesity-device-the-latest-victims-of-the-ipo-haircut/comment-page-1/#comment-778626 VentureBeat » IPO roundup: Is the window slamming shut for life sciences? Thu, 07 Feb 2008 15:03:31 +0000 http://venturebeat.com/2007/11/14/enteromedics-and-its-risky-obesity-device-the-latest-victims-of-the-ipo-haircut/#comment-778626 [...] have to look back to three companies that priced at a discount in November — EnteroMedics (Nov. 14, now up three percent), ARYx Therapeutics (Nov. 7, now down 25 percent) and BioForm Medical (also [...] [...] have to look back to three companies that priced at a discount in November — EnteroMedics (Nov. 14, now up three percent), ARYx Therapeutics (Nov. 7, now down 25 percent) and BioForm Medical (also [...]

]]> http://venturebeat.com/2007/11/14/enteromedics-and-its-risky-obesity-device-the-latest-victims-of-the-ipo-haircut/comment-page-1/#comment-634958 www.topweightlosssecrets.info » EnteroMedics and its risky obesity device, the latest victims of … Thu, 15 Nov 2007 12:15:47 +0000 http://venturebeat.com/2007/11/14/enteromedics-and-its-risky-obesity-device-the-latest-victims-of-the-ipo-haircut/#comment-634958 [...] David P. Hamilton placed an interesting blog post on EnteroMedics and its risky obesity device, the latest victims of ….Here’s a brief overview:Paul, Minn., device maker working on a neuromodulation implant for treating obesity, slashed its expected IPO pricing by half, lowering it to a range of $8 to $9 instead of its earlier estimate of $14 to $16. The company’s latest SEC … [...] [...] David P. Hamilton placed an interesting blog post on EnteroMedics and its risky obesity device, the latest victims of ….Here’s a brief overview:Paul, Minn., device maker working on a neuromodulation implant for treating obesity, slashed its expected IPO pricing by half, lowering it to a range of $8 to $9 instead of its earlier estimate of $14 to $16. The company’s latest SEC … [...]

]]> http://venturebeat.com/2007/11/14/enteromedics-and-its-risky-obesity-device-the-latest-victims-of-the-ipo-haircut/comment-page-1/#comment-633726 VentureBeat » Life sciences briefing: Wednesday, Nov. 14, 2007 Wed, 14 Nov 2007 23:19:45 +0000 http://venturebeat.com/2007/11/14/enteromedics-and-its-risky-obesity-device-the-latest-victims-of-the-ipo-haircut/#comment-633726 [...] UPDATED: Expanded items on Skyline Ventures, Ambit, and Molecular Vision, and moved EnteroMedics to a new item here. [...] [...] UPDATED: Expanded items on Skyline Ventures, Ambit, and Molecular Vision, and moved EnteroMedics to a new item here. [...]

]]>